

Evaluation of a Mobile HFCWO Device in Patients with Cystic Fibrosis¹

Leemans G.¹; De Hondt A.¹; Ides K.²; Van Holsbeke C.¹; Belmans D.¹; Becker B. C.³; Van Hoorenbeeck K.⁴
1. Fluida, Inc., Kontich, Belgium; 2. Universiteit Antwerpen, Antwerpen, Belgium; 3. Clinical Research, Hill-Rom, St. Paul, MN, USA; 4. Pediatrics, Universitair Ziekenhuis, Antwerpen, Belgium.

Introduction

High-frequency chest wall oscillation (HFCWO) therapy for airway clearance is common in patients with cystic fibrosis (CF). A limitation is the requirement for AC power during therapy. A mobile HFCWO device that generates chest wall pressure and oscillating airflow comparable to standard HFCWO devices is now available. The goal of this study was to evaluate the effectiveness of this mobile HFCWO device (the Monarch[®] Airway Clearance System), compared to a standard HFCWO device (The Vest[®] Airway Clearance System).

Methods

This was a randomized, open-label crossover study. Subjects received HFCWO with both devices. Inclusion criteria were age ≥ 15 years, stable CF medications (prior 4 weeks) and daily sputum production. Patients were randomized to the Monarch[®] System or The Vest[®] System on day 1. Each subject received alternate therapy after a washout period (2–7 days). Subjects performed 1 morning treatment each day. Four subjects performed an afternoon treatment, as well. Treatments were 30 minutes at multiple frequencies, with intensity settings of 6 to 10 on each device.




Figure 1. Comparison of Wet Sputum Weight, Monarch[®] System vs. The Vest[®] System ($p=0.77$)^{1,3}

Subjects collected sputum during their 30-minute therapy and 1-hour post-therapy. Mean wet weight of sputum was compared. To further evaluate Monarch[®] System therapy, CT scans were done before therapy and after sputum collection. Brody scores were performed on CT scans by a radiologist blinded to the study. Functional respiratory imaging (FRI)² was used to evaluate airway geometry using CT scans.

Results

Eight (8) subjects completed the study. Mean wet sputum weight (Figure 1) was similar between the Monarch System and The Vest[®] System therapy ($6,536 \pm 8,554$ vs. $5,801 \pm 5,824$ mg, $p=NS$). Brody scores showed statistically significant improvement following therapy with the Monarch[®] System. FRI results showed statistically significant differences in airway geometry and patency, pre-therapy vs. post-therapy with the Monarch[®] System, suggesting mucus shifting. See Table 1 for Brody scores and FRI results.

Parameter	Pre-Monarch [®] System Therapy Measurements	Post-Monarch [®] System Therapy Measurement	P-value
Brody Scores	57.71 ± 16.55	55.2 ± 16.98	$p=0.001$
FRI (iVaw)	49.442 ± 50.117	44.516 ± 49.637	$p<0.001$

Table 1. Brody Scores and FRI Measurements for the Monarch[®] System

Conclusions

The Monarch[®] System was comparable to The Vest[®] System for sputum production. Further evaluation of the Monarch System post-therapy found airway clearance improvement is shown by improved Brody scores and FRI results.

Hill-Rom is a leading global medical technology company with more than 10,000 employees worldwide. We partner with health care providers in more than 100 countries, across all care settings, by focusing on patient care solutions that improve clinical and economic outcomes in five core areas: **Advancing Mobility, Wound Care and Prevention, Patient Monitoring and Diagnostics, Surgical Safety and Efficiency and Respiratory Health**. Our innovations ensure caregivers have the products they need to help diagnose, treat and protect their patients; speed up recoveries; and manage conditions. **Every day, around the world, we enhance outcomes for patients and their caregivers.** Learn more at hill-rom.com.

References

1. Leemans G, De Hondt A, Ides K, et al. Evaluation of a mobile HFCWO device in patients with cystic fibrosis. *Pediatric Pulmonology*. September 2018;53(S2):S1-S481.
2. As described by: De Backer JW, Vos WG, Vinchurkar SC, et al. Validation of computational fluid dynamics in CT-based airway models with SPECT/CT. *Radiology*. December 2010;257(3):854-62. doi: 10.1148/radiol.10100322.
3. Analysis conducted using linear mixed effects model.

Monarch® and The Vest® are registered trademarks of Hill-Rom Services PTE Ltd.
Enhancing Outcomes for Patients and Their Caregivers® is a registered trademark of Hill-Rom Services, Inc.

Hill-Rom reserves the right to make changes without notice in design, specifications and models. The only warranty Hill-Rom makes is the express written warranty extended on the sale or rental of its products.

©2018 Hill-Rom Services PTE Ltd. ALL RIGHTS RESERVED.
209191 rev 2 03-OCT-2018 ENG – US

For further information about this product or a service, please contact your local Hill-Rom representative or visit our webpage:

800.426.4224

www.respiratorycare.hill-rom.com

Enhancing outcomes for patients and their caregivers:

Hill-Rom